To evaluate how characterization of genetic alterations can help in the elucidation of liver carcinogenesis pathways, 137 tumors were analyzed. Methods: High-density allelotype, p53, Axin1, and ␤-catenin gene mutations were determined. Alterations were analyzed according to clinical parameters. Results: Tumors could be divided into 2 groups according to chromosome stability status. In the first group, demonstrating a chromosome stability, ␤-catenin mutation associated with chromosome 8p losses were frequently found as the single genetic alterations. ␤-catenin mutations were associated with large tumor size and with negative hepatitis B virus status. In the second group, demonstrating a chromosome instability, the most frequent allelic losses were on chromosome 1p, 4q, 6q, 9p, 13q, 16p, 16q, and 17p; Axin1 and p53 were frequently mutated. All of these alterations, except losses on 6q and 9p, were associated with hepatitis B virus infection. P53 mutations, 17p, 13q losses, and a high value of the fractional allelic loss index were associated with poor differentiated tumors, independently of risk factors. Finally, in the whole series, chromosome 9p and 6q losses were associated with poor prognosis. Conclusions: Two main pathways defined by genetic alterations show different risk factors and clinical characteristics. Furthermore, loss of chromosome 9p or 6q is an independent prognostic indicator.
H epatocellular carcinoma (HCC) is one of the most frequent malignant tumors in developing countries. HCC risk factors, such as infection by hepatitis B and C viruses (HBV and HCV), cirrhosis of any etiology, primary hemochromatosis, and prolonged exposure to Aflatoxin B1 are well characterized. 1 However, the carcinogenesis mechanisms are poorly understood and seem to differ according to the risk factor involved. For example, at least 2 different carcinogenesis mechanisms involving HBV infection have been described. In rare cases, insertional mutations have been described in which HBV integration at specific sites activates endogenous genes such as retinoic acid ␤-receptor, cylin A, mevalonate kinase, and SERCA-1. [2] [3] [4] [5] In addition, viral proteins, such as HBX, can present transactivating activity, and the oncogenic potential of HBX has been extensively studied (for review, see Andrisani and Barnabas 6 ). Except for exposure to Aflatoxin B1, which has been shown to cause a specific mutation in the p53, no clear specific oncogenic mechanism can be attributed to other HCC risk factors.
As in other solid tumors, a number of genetic alterations have been described in HCC, and more than 20 genes, implicated in at least 4 carcinogenesis pathways, have been shown to be altered (for review, see Feo et al. 7 and Buendia 8 ). The genes most frequently mutated in HCC are p53, and the Wnt/wingless carcinogenesis pathways are the most frequently altered in HCC. A specific mutation in codon 249 of the p53 gene was found in about 50% of HCC in populations exposed to aflatoxin B1. 9, 10 In contrast, patients who have not been exposed to this carcinogen have a lower prevalence of p53 gene mutations (10%-30%) and codon 249 is rarely altered. 11, 12 Broadly, p53 alterations have been proposed to be associated with poorly differentiated, large tumors and with a lower overall survival. [13] [14] [15] [16] Activation of the Wnt/wingless pathway can be caused by a stabilizing mutation of the ␤-catenin gene (15%-25% of cases) or by an inactivating mutation of the Axin1 gene (5% of cases). [17] [18] [19] [20] Recently, ␤-catenin alterations have been found to be associated with HCC presenting a low rate of loss of heterozygosity (LOH), 19 with HBV-negative tumors, and with a better survival of the patients. 21 Less frequently observed in HCC are inactivating RB1 mutations, suppression of methylation of P16, overexpression of cyclin D1, and increased RB1 degradation by overexpression of gankyrin leading to the alteration of the RB1 pathway. [22] [23] [24] Finally, rare IGF2R, SMAD2, and SMAD4 inactivating gene mutations can alter the transforming growth factor ␤ pathway. [25] [26] [27] Most of the genes mutated in HCC are tumor suppressor genes, and frequent allelic losses (LOH) leading to the biallelic inactivation have been described. Comparative genomic hybridizations and high-density allelotypes show recurrent allelic losses on chromosomes 1p, 4q, 6q, 8p, 9p, 13q, 16p, 16q, and 17p. 28 -30 For chromosomes 17p, 13q, 9p, 6q, and 16p, LOH could be related to p53, RB1, p16, IGF2R, and Axin1 inactivation, respectively. Identification of the presumed tumor suppressor genes on chromosomes 1p, 4q, 8p, and 16q remains an open area of research.
Because most of the genetic alterations have been studied individually and because HCC forms a group of heterogeneous tumors, a comprehensive characterization of the genetic alterations in HCC is an outstanding problem. To contribute to this characterization, we have analyzed a large number of genetic alterations in the same series of tumors. The goal of our study is to identify the relations between genetic alterations and the various clinical parameters defining HCC.
Patients and Methods

Patients and Samples
Primary hepatocellular carcinoma and matched nontumor liver tissues were obtained from 137 patients during hepatectomy (n ϭ 109), liver transplantation (n ϭ 26), or at autopsy (n ϭ 2) in 4 French surgical departments from 1992 to 1998. Fibrolamellar carcinomas were excluded from the series. Tumor tissue samples were dissected and nontumor tissues (Ͼ50 mg) were taken as far from the tumor as possible. Tissues were stored at Ϫ80°C until DNA extraction using the Qiaquick extraction kit (Qiagen, Courtaboeuf, France). DNAs were quantified by fluorometry (Fluoroskan Thermo Labsystem, Cergy-Pontoise, France).
The patients were born in France (100 cases), the Mediterranean area (13 cases), sub-Saharan Africa (11 cases), the Antilles (6 cases), and Asia (7 cases). The mean age of the patients was 59 years (range, 18 -85 years) and the sex ratio (M:F) was 4:1. The HBV status was determined by the presence of a hepatitis B surface antigen (HBsAg), which was detected in the serum in 37 cases. All tumor and matching nontumor DNAs (20 ng) were amplified for the HBX (primer 1 and 7 described by Paterlini et al. 31 ) and preS genes (primers preS1F: CACCATATTCTTGGGAACAAG and preS1R: TTGGGGT-TGAAGTCCCAATC) using a touchdown polymerase chain reaction (PCR) procedure (annealing range, 60°C-52°C, 35 cycles) with primers (0.3 mol/L) and Taq polymerase (1 U; Applied Biosystems Courtaboeuf, France). Sensitivity of the HBX and PreS PCR (50 and 100 HBV genome detected per 2000 cells tested, respectively) have been determined on DNA extracted from HBV-infected serum previously quantified by Quantiplex HBV DNA method (Bayer Diagnostics, Emeryville, CA). Reactions with no viral DNA were included in each set of amplifications to control for unwanted contamination. Using this protocol, a cryptic hepatitis B infection was detected in 5 cases negative for HBsAg in their sera. Among these 5 cases, all but 1 had anti-HBc antibodies. These 5 patients with an HBV cryptic infection were recorded in the group of HBV patients. HCV infection was detected in 40 patients using enzyme-linked immunosorbent assays, and these cases were confirmed by RIBA 3. Eight patients showed evidence for both HBsAg and antibodies against HCV in their sera. No evidence for either HBV or HCV infection was found in 64 patients. In this group, 34 patients showed alcohol abuse and 7 patients had a hemochromatosis, whereas in 23 cases HCC developed in the absence of a known risk factor. The 137 tumors of the series were classified according to their risk factors and characteristics of the nontumoral liver (Table 1) .
Pathologic features were also recorded for each tumor. The histologic grade of tumor differentiation was assigned according to the Edmondson and Steiner grading system. After grading, tumors were classified in 2 groups (i.e., grade I ϩ II and grade III ϩ IV). In 130 cases, the preoperative ␣-fetoprotein serum level was available. Time of survival after complete tumor resection was greater than 3 months in 84 patients, and the mean follow-up was 30 months (range, 3-105 months). 
Gene Mutation Analysis
Exons 5, 6, 7, and 8 of p53 were screened by DGGE, whereas exons 2, 3, 4, 9, 10, and 11 were screened by direct sequencing using primers and PCR conditions as described. 32 ␤-catenin mutations were screened in exons 2-4 by direct sequencing using primers as described. 19 Axin1 mutations were screened by dHPLC (Varian, Les Ulis, France) in all exons except exons 1 and 5, which were sequenced directly. Exons of Axin1 were amplified as described previously. 20 In all cases, direct sequencing was performed on PCR products purified with a Qiaquick PCR purification kit using big dye terminator chemistry on an Applied Biosystems A377 sequencer (Applied Biosystems, Courtaboeuf, France). Analyses were performed using Factura and Autoassembler softwares (Applied Biosystems). The somatic origin of mutations was confirmed by sequencing DNA derived from the nontumor corresponding tissues.
Characterization of LOH
Allelic losses were determined by genotyping 400 markers from the LMS2 microsatellites panel (Applied Biosystems) on tumor DNA and comparing those genotypes with those from the matching nontumor DNA. PCR amplifications were performed on a 9600 or 9700 Perkin-Elmer DNA cycler (Applied Biosystems) in a final volume of 5 L using the following procedure: initial denaturation step, 95°C for 12 minutes, 10 cycles with a denaturation step at 94°C for 15 seconds, annealing at 55°C for 15 seconds, extension at 72°C for 30 seconds, 10 cycles (89°C 15 seconds, 55°C 15 seconds, and 72°C 30 seconds), followed by a final extension at 72°C for 10 minutes. For each DNA amplification, Taqgold (0.5 U; Applied Biosystems) was used with 15 ng of genomic DNA, 1-6 pmol of each specific primer, 0.25 mmol/L deoxynucleoside triphosphate and 2.5 mmol/L MgCl 2 . Two to 5 loci were coamplified in the same PCR reaction. PCR products were loaded on a 377 Applied Biosystems sequencer according to manufacturer recommendations. Genotyping analyses were performed using the Genotyper software (Applied biosystems) with an automatic data-processing trace program developed in the laboratory and available on request. 33 A locus was considered lost if the intensity of an allele compared with the intensity of the second allele was decreased by at least a factor 2 in the tumor tissues when compared with the normal ones.
Statistical Methods
Qualitative and categorized quantitative variables were compared to each other using 2 test with Yates' correction when necessary. Hierarchical clustering analysis of the genetic alterations was performed using Cluster 2.51 software (␤-test version; gift of Gavin Sherlock, Stanford University). For all the variables, the normal status was encoded with the corresponding negative value. Data were analyzed with the Pearson correlation measure without partition.
Survival time was calculated from the date of surgical resection. Patients who were lost to follow-up, alive at the time of the study, or dead from cause other than liver cancer were treated as censored events. Patients treated by liver transplantation (25 cases) or by palliative resection (17 cases), patients lost to follow-up less than 1 month after resection, patients who died during the surgical procedure (6 cases), and patients with tumors removed during autopsy (4 cases) were excluded from the survival analysis. Survival curves were calculated according to the Kaplan-Meier method with Statview 4.5 software (Abacus Concept, Berkeley, CA) and differences were assessed using the log rank test. Cox multivariate proportional hazards regression analyses were performed to evaluate the relative influence of different prognostic factors using STATA software (Stata Corporation, College Station, TX).
Results
Allelotyping Results
A total of 335 microsatellite markers distributed among the 39 autosomal chromosome arms were characterized for each tumor and matched nontumor DNAs. More than 70% of the loci were informative per individual, and the status of more than 99.5% of the chromosome arms have been defined as conserved or deleted in the tumor. To avoid artifactual results, for all cases, the LOH status of a chromosome arm was attributed if at least 2 adjacent markers showed LOH. In all cases, more than 99% of the markers presented 1 or 2 alleles with the same size in tumor and matching nontumor tissue. Therefore, none of the 137 tumors filled the criteria defining a microsatellite instability pattern. 34 Large variations in chromosome arm loss frequencies were observed ( Figure 1 ). Ten chromosome arms, i.e., 8p (48%; 95% confidence interval [CI], 40 -56), 17p (45%; 95% CI, 36 -53), 4q (38%; 95% CI, 30 -46), 1p (33%; 95% CI, 26 -41), 16q (30%; 95% CI, 23-38), 13q (31%; 95% CI, 24 -39), 6q (29%; 95% CI, 22-37), 16p (24%; 95% CI, 18 -32), 1q (22%; 95% CI, 16 -30) , and 9p (20%; 95% CI, 14 -27), were deleted with a frequency higher than 20%. This latter value represents the 99% confidence upper limit for the overall rate of random chromosome loss in this series, suggesting the existence of a potentially causative genetic alteration. The FAL index (Fraction of evaluable autosomal arms demonstrating allelic deletion) was calculated, and the mean FAL index 35 for all tumors was 0.14 Ϯ 0.11 (range, 0 -0.59; median, 0.128 corresponding to 5 chromosome arms lost out of the 39 tested).
Overall Frequency and Spectrum of p53, ␤-Catenin, and Axin1 Mutations Mutations in p53 gene were found in 36 of 137 HCCs screened (26% of the cases). All but 4 were point mutations (21 transversions and 11 transitions). In the remaining 4 cases, 2 were small insertions and 2 were small deletions (Table 2) . Among these mutations, 25 led to an amino acid substitution and 10 led to a premature stop codon by frameshift (3), non-sense mutation (5), or by mutation occurring in consensus splice site (2) . In the remaining case, an inframe-deletion was observed between codons 208 and 217. In 8 cases, the specific R249S mutation was found. All the patients presenting this mutation were HBV positive. The geographic origins of these patients were Africa (Mauritania, Benin, Mali), Haiti (1 case), Asia (2 Vietnam), and France (2 cases). In these latter 2 patients, 1 received chemotherapy and radiotherapy treatment for a Hodgkin lymphoma 15 years before the HCC diagnosis and the 1 remaining was a patient without known exposure to aflatoxin B1.
In 26 (19%) cases, a ␤-catenin mutation was found in exon 3. All but 2 were point mutations, with the remaining cases being deletions of 27 and 381 base pairs, respectively (Table 3) . Tumors CHC072 and CHC131 were found to have 4 and 2 different mutations, respectively. In 22 cases, ␤-catenin point-mutations alter 1 of the 4 serine or threonine residues, which are targets for phosphorylation by GSK3 and are essential for the downregulation of ␤-catenin. Major hot spots were found on amino acids S33, T41, and S45.
Axin1 alterations have been found in 12 of 137 screened cases (Table 4) . Among them, point mutations represented half of the cases, whereas the other alterations were small deletions (4 cases), a homozygous deletion (1 case), and a small duplication (1 case). In all but 2 cases (CHC079 and CHC080), Axin1 mutations generated a stop codon, a frameshift, or a deletion of a large part of the Axin1 gene. In the remaining 2 cases, a transversion generated an amino acid substitution at codon numbers 395 and 131, respectively. In all but 2 cases (CHC080 and CHC190), Axin1 mutations were 
Tv, transversion; Ts, transition, D, deletion, I, insertion; B, HBV infection; C, HCV infection; A, alcohol abuse; H, hemachromatosis; U, unknown risk factor.
associated with LOH of the second allele on chromosome 16p as revealed by genotyping.
Correlations and Hierarchical Analyses of the Genetic Alterations
To test associations between genetic alterations, correlations between gene mutations and chromosome LOH were studied in the series of 137 tumors. Correlations were sought by analyzing p53, Axin1, and ␤-catenin mutations together with the 10 most frequently deleted chromosome arms and the FAL index (Table 5) . A strong correlation was evidenced between a FAL index value superior to 0.12, p53 mutations, and the loss of chromosomes 1p, 4q, 6q, 16p, and 17p. On the contrary, the ␤-catenin mutations are related to a low FAL index value (Ͻ0.12). To better dissect the associations between these 13 genetic alterations, a hierarchical classification of these alterations has been performed with the software Cluster by analyzing 130 tumors presenting at least 1 of these alterations ( Figure 2 ). As expected, the p53 mutations were closely related to LOH on chromosome 17p corresponding to the inactivation of the second allele of p53. In the same way, the correlation between Axin1 mutations and LOH on chromosome 16p can be related to the inactivation of the second allele of this gene. Moreover, the smallest common region of deletions defined on chromosome 16p and 17p included the chromosome location of the Axin1 and p53 genes, respectively. All deleted chromosome arms associated with a high FAL index value were gathered in 1 branch (branch I, Figure 2 ) of the hierarchical tree defining 3 clusters. Mutations in p53 gene and chromosome 17p LOH were associated in a first cluster, as 6q and 9p LOH defined a second one. Chromosome 1p, 4q, 13q, 16p, and 16q LOH were associated in a third cluster with the Axin1 gene mutations. Chromosome 1q was not closely related to another alteration. Besides these genetic alterations associated with a high FAL index value, the second branch of the hierarchical tree (branch II) involved ␤-catenin mutations associated with chromosome 8p LOH.
Correlations Between Clinical Characteristics and Genetic Alterations
Correlation analyses were performed considering the 10 chromosome arms that had shown the highest LOH frequency, the FAL index value, and the 3 gene mutation results with 9 clinical or histologic parameters (Table 6 ). First, 3 genetic alterations, chromosomes 1q, 6q, and 9p LOH, did not show association with any clinical characteristics. Second, a strong association of HBV infection was found with a FAL index superior to 0.12, p53, Axin1 mutations, chromosome 1p, 4q, 13q, 16p, and 16q LOH (Table 6) . Except for p53, these significant associations were preserved when patients showing a p53 R249S mutation specific of Aflatoxin B1 exposure were removed from the analysis (all these patients were infected by HBV). Third, a low degree of tumor differentiation was significantly linked to p53 mutations, chromosome 17p, 13q LOH, and a high value of the FAL index. Because HBV-infected tumors were associated with a low degree of differentiation, adjusted Mantel-Haentzel tests for HBV infection status were performed. Chromosome 17p, 13q LOH, p53 mutations, and a high value of the FAL index remained significantly associated with a low degree of differentiation. Three of these alterations (p53 mutations, chromosome 17p LOH, and high FAL index value) and the chromosome 4q LOH were associated with a high ␣-fetoprotein (AFP) serum level. Fourth, non-HBV and large-size tumors were found to be associated with ␤-catenin mutations, which were significantly more frequently found in tumors with a low value of FAL index. Last, tumors developed on noncirrhotic liver were significantly more frequently associated with 2 alterations, chromosome 13q and 8p LOH (Table 6 ).
Survival Analysis
Overall patient survival was analyzed according to the different genetic alterations on a subset of 85 patients treated by complete resection of their tumor (see Materials and Methods). A significant correlation was observed between 3 genetic alterations (LOH on chromosome 9p, 6q, and FAL index value Ͼ0.12) and shorter survival (Figure 3 A-C) . Among the clinical and biological parameters, only vascular invasion and serum AFP level were associated with a poor prognosis (P ϭ 0.002 and P ϭ 0.004, respectively). Because of the strong correlation between chromosome 6q and 9p LOH, a new bimodal variable (6q/9p LOH) was generated (value 0 for no loss on 6q and 9p, value 1 for loss on 6q or 9p) and included in a Cox model. As shown in Table 7 , the presence of vascular invasion, an AFP value Ͼ 20 IU, and the presence of chromosome 6q or 9p LOH were independent indicators of the poor prognosis.
Discussion
This study provides an exhaustive analysis of the relations that exist between the genetic alterations frequently found in HCC and the histoclinical characteristics of the tumors. For the first time, search for LOH on all chromosome arms and for mutations in 3 genes, P53, ␤-catenin, and Axin1, were carried out on the same series of tumors. Because the previously published series have investigated only a specific subset of genetic alterations, the correlations existing between all the different genetic alterations were impossible to evaluate. Furthermore, the actual importance of the relations existing between each genetic alteration and the clinical characteristics of hepatocellular carcinoma was difficult to establish. These drawbacks were bypassed in the present series by the large number of studied cases and by our comprehensive analysis of the genetic alterations. Moreover, the 3 most frequent etiologic groups, HBV infection, HCV infection, and alcoholic disease, were equally represented in this series.
Allelotypes have been determined by comparing tumor DNA with the matched nontumor DNA provided from distant liver tissue. The informativity of the differ- ent markers observed in this series was not different from that Genome Database (i.e., mean, 72%; range, 45-85). Furthermore, because the nontumor samples were not focused on regenerative macronodules and no difference in the per marker hereterozygosity rate was observed between the noncirrhotic and cirrhotic liver, possible genetic alterations in nontumor liver tissues should not significantly interfere with LOH results in the tumors tested. LOH seemed to be the most frequent genetic alteration observed in this series because only 7 tumors showed no loss of any chromosome arms. Half of the patients showed LOH on more than 5 chromosomal arms (i.e., FAL index Ͼ 0.12), reflecting a chromosomal instability as described by Cahill et al. 36 and defining a first hepatocarcinogenesis mechanism (Figure 4 ). All genetic alterations but 2 (8p LOH and ␤-catenin mutations) were closely related to a high value of FAL index. Among these alterations, LOH of 5 chromosome arms (1p, 4q, 13q, 16p, and 16q) and the Axin1 and p53 gene mutations were seen to be linked to HBV infection. Globally, chromosomal instability was also closely related to the presence of HBV infection (81% of the HBV tumors present at FAL index Ͼ 0.12 vs. 40% of the HBVnegative tumors). This relationship could explain the variation of FAL index values observed in different published series that also showed different distributions of risk factors (for review, see Buendia 8 ). In this group of alterations, p53 mutations were found in 26% of the analyzed cases. In 8 cases, an R249S mutation was asso- ciated with an HBV infection. Among these patients, 6 came from an African, Asian, or Haitian area with endemic exposure to aflatoxin B1. In contrast, 2 patients coming from France have no known Aflatoxin exposure. Among the 7 hemochromatosis-related tumors, 3 p53 mutations were found. The A220G mutation previously described in one third of the British hemochromatosis patients was not observed in our study. 37 In the present series, chromosome 13q LOH and p53 mutations were correlated with poor differentiation status of tumors, a correlation that remained significant even after adjustment for HBV infection status. These correlations were in agreement with the previous p53 analyses in HCC (for review, see Buendia 8 ). Although different experimental models suggested the role of p53 mutations and HBV infection in chromosome instability occurrence, 38 -41 it is interesting to note that in the present series, in 28 of 75 cases (37%), the chromosomal instability observed could not be related to p53 mutations or to HBV infection. This last group of tumors should be further investigated to search for new factors inducing chromosome instability in HCC. The second hepatocarcinogenesis mechanism is defined by ␤-catenin mutations associated with chromosome 8p LOH in a context of chromosome stability (Figure 4) . These 2 genetic alterations seemed to be early events in the carcinogenesis because they frequently occurred apart from any other LOH or mutations in the tumors. The ␤-catenin mutations were found preferentially among patients that had not been infected by HBV and were positively correlated to the tumor size. Thus, in a context of chromosome stability (FAL Ͻ 0.12), these genetic alterations define a particular mechanism of HCC carcinogenesis through the activation of a Wnt pathway. However, in the group of patients not infected by HBV, 35% of HCC cases did not show gene mutation or specific chromosome LOH. In this last group of tumors, the likelihood of unknown gene amplification or activating gene mutation is high and should also be further investigated. Concerning the group of HCV-related tumors, no significant relationship could be evidenced with any genetic alterations even if the group of HBV tumors was excluded from the analysis. Therefore, HCV-related tumors cannot be discriminated from other non-HBV tumors.
Although clinicopathological parameters of HCC have not been previously studied in relation to the FAL index, a lower prevalence of allelic losses on specific chromosome segments has been associated with early HCC. [42] [43] [44] On the other hand, a higher prevalence of allelic losses has been correlated with tumor aggressiveness. 45 Evidence was provided here for a positive relationship between a high FAL index value, the chromosomes 6q and 9p LOH, and a shorter survival. Only these latter 2 alterations retained an independent prognostic value in a multivariate analysis. In contrast to what was observed by Hsu et al., 21 there is no evidence for a favorable prognostic role of ␤-catenin mutations in the present work. This discordant result could be due to different risk factors and/or geographic distribution. Additional studies using a prospective series should clarify the prognostic value of these genetic alterations.
In summary, HCC could be divided into 2 major groups based on the existence of a chromosome instability. LOH at specific chromosome arms and gene mutation screenings seemed to efficiently identify subgroups of tumors that had different clinical characteristics, i.e., tumor size, etiologic risk factor, cellular differentiation, and overall survival. However, common biological pathways may be altered in the different subgroups defined by genetic alterations. For example, the Wnt/wingless pathway could be activated through a stabilizing ␤-catenin mutation in a context of chromosome stability in an HBV-negative tumor, whereas it could be activated through biallelic inactivation of the Axin1 gene in a context of chromosomal instability in HBV-infected tumors. In the future, transcriptome analyses of HCC should elucidate the relationship between biological carcinogenesis pathways and the clinical parameters.
